Haikuo Zhang serves as the Director, Associate Director, and Senior Principal Scientist of Translational Research at GluBio Therapeutics Inc., where he plays a pivotal role in advancing innovative therapeutic strategies in oncology and immunology. With over a decade of experience in drug discovery and development,...
Haikuo Zhang serves as the Director, Associate Director, and Senior Principal Scientist of Translational Research at GluBio Therapeutics Inc., where he plays a pivotal role in advancing innovative therapeutic strategies in oncology and immunology. With over a decade of experience in drug discovery and development, Haikuo has established himself as a leading expert in small molecules, targeted protein degradation, immunotherapy, and oncolytic viruses. His extensive background encompasses early drug discovery and target validation, where he has successfully identified and characterized novel therapeutic targets that have the potential to transform treatment paradigms.
As a founding member of the translational research team, Haikuo is instrumental in supporting the discovery and development of both preclinical and clinical programs. His work includes biomarker discovery and validation, which are critical for patient stratification and ensuring that therapies are tailored to the right populations. He evaluates program differentiation strategies and indication selection, leveraging his deep understanding of pharmacodynamics and efficacy analysis through multiparameter flow cytometry (FACS) techniques. Additionally, Haikuo is adept at developing drug combination strategies that enhance therapeutic efficacy while minimizing resistance.
His expertise in in vitro and in vivo pharmacology, coupled with a strong foundation in molecular biology, cell biology, and biochemistry, enables him to drive innovative research initiatives at GluBio. Haikuo's proficiency with animal models, transgenic mice, and advanced assay development further underscores his commitment to translating scientific discoveries into viable clinical applications. As he continues to push the boundaries of translational research, Haikuo Zhang remains dedicated to improving patient outcomes through cutting-edge therapeutic solutions.
